The study, which analyzes the $36 billion U.S. implantable medical device, projects orthopedic implants to be one of the fastest growing and remain the largest segment.
Pacing devices are expected to lead gains among cardiovascular implants. Neurostimulators and drug implants are also expected to see strong growth.
Medical implant sales will face challenges presented by attempts from payors to tighten control over maximum payment for implantations, but the study indicates the cost-savings opportunities presented through the use of implants will help with growth, according a news release on the Freedonia report.
Related Articles on Implants:
Proposed Bill Would Tighten FDA Oversight of Medical Devices
5 Ways to Improve Profitability at Pain-Driven ASCs
Developing the ASC Marketplace through Effective Implantable Device Benefit Management
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.